DCO:NYSEDucommun Incorporated Analysis
Data as of 2026-09-19 - not real-time
$166.25
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
At $166.25, Ducommun Incorporated shows no decisive moving-average alignment, leaving the trend neutral. It has lost 17.5% over the past 30 days. Momentum indicators put RSI at 41.1 (neutral) with MACD reading bearish. The recent range runs from support at $156.31 up to resistance at $193.99.
On valuation the read is fair — earnings multiple of 31.0 versus a 27.6 sector average, above the peer group. The average analyst target implies 27.5% above today's level. Revenue is growing at 11.8% on a -2.5% profit margin.
The composite risk read is 7/10, putting it in elevated territory. With 30-day volatility of 38.3%, a beta of 1.38 and a maximum drawdown of 20.5%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 4/10.
On valuation the read is fair — earnings multiple of 31.0 versus a 27.6 sector average, above the peer group. The average analyst target implies 27.5% above today's level. Revenue is growing at 11.8% on a -2.5% profit margin.
The composite risk read is 7/10, putting it in elevated territory. With 30-day volatility of 38.3%, a beta of 1.38 and a maximum drawdown of 20.5%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 4/10.
Top Market Events
Yahoo Finance1monDucommun Incorporated DCO Q2 FY2026 earnings call transcriptDucommun delivered record Q2 2026 results...COSTA MESA, Calif., Aug. 27, 2026 GLOBE NEWSWIRE -- Ducommun Incorporated NYSE: DCO 'Ducommun” or the 'Company”...COSTA MESA, Calif., Aug. 26, 2026 GLOBE NEWSWIRE -- Ducommun Incorporated NYSE: DCO 'Ducommun” or the 'Company”...
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 3/10
Key Factors
- Trading above the 200-day average of 142.70
- MACD momentum is negative
- 30-day price change of -17.5%
Medium Term
1–3 yearsNeutral
Model confidence: 3/10
Key Factors
- P/E of 31.0 versus sector average of 27.6
- Trading above the 200-day average of 142.70
- Analyst targets imply +27.5% versus the current price
Long Term
> 3 yearsNeutral
Model confidence: 4/10
Key Factors
- P/E of 31.0 versus sector average of 27.6
- Negative profit margin of -2.5%
- Analyst targets imply +27.5% versus the current price
Key Metrics & Analysis
Financial Health
Revenue Growth11.80%
Profit Margin-2.45%
P/E Ratio31.0
ROE-3.03%
ROA4.97%
Debt/Equity48.49
P/B Ratio3.6
Op. Cash Flow$-11800000
Free Cash Flow$57.5M
Industry P/E27.6
Technical Analysis
TrendNeutral
RSI41.1
Support$156.31
Resistance$193.99
MA 20$172.65
MA 50$179.79
MA 200$142.70
MACDBearish
VolumeIncreasing
Fear & Greed Index94.98
Valuation
Fair Value$57.78
Target Price$212.00
Upside/Downside27.52%
GradeFair
TypeGrowth
Risk Assessment
Beta1.38
Volatility38.29%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.